BIO-TECHNE Corp Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIO-TECHNE Corp stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $20.89M.
- BIO-TECHNE Corp stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $15.77M.
- BIO-TECHNE Corp stock issued during period, value, stock options exercised for the quarter ending 2023-12-31 was $3.84M, a 24.32% decline year-over-year.
- BIO-TECHNE Corp stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was -$2.58M.
- BIO-TECHNE Corp stock issued during period, value, stock options exercised for fiscal 2024 was $39.89M, a 1330.37% increase from fiscal 2023.
- BIO-TECHNE Corp stock issued during period, value, stock options exercised for fiscal 2023 was $2.79M, a 95.42% decline from fiscal 2022.
- BIO-TECHNE Corp stock issued during period, value, stock options exercised for fiscal 2022 was $60.90M, a 22.23% increase from fiscal 2021.
- BIO-TECHNE Corp stock issued during period, value, stock options exercised for fiscal 2021 was $49.82M, a 26.55% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-09-30 | $20.89M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $39.89M 10-K · filed 2024-08-22 | |
| 2024-03-31 | $15.77M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $3.84M 10-Q · filed 2024-05-06 | |
| 2023-09-30 | -$2.58M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $2.79M 10-K · filed 2024-08-22 | |
| 2023-03-31 | -$8.86M 10-Q · filed 2024-05-06 | |
| 2022-12-31 | $5.08M 10-Q · filed 2024-05-06 | |
| 2022-09-30 | -$2.00M 10-Q · filed 2024-05-06 | |
| 2022-06-30 | $60.90M 10-K · filed 2024-08-22 | |
| 2022-03-31 | $10.49M 10-Q · filed 2023-05-08 | |
| 2021-12-31 | $18.61M 10-Q · filed 2023-05-08 | |
| 2021-09-30 | $22.87M 10-Q · filed 2023-05-08 | |
| 2021-06-30 | $49.82M 10-K · filed 2023-08-23 | |
| 2021-03-31 | $16.99M 10-Q · filed 2022-05-09 | |
| 2020-12-31 | $14.27M 10-Q · filed 2022-05-09 | |
| 2020-09-30 | $13.73M 10-Q · filed 2022-05-09 | |
| 2020-06-30 | $67.83M 10-K · filed 2022-08-24 | |
| 2020-03-31 | $10.03M 10-Q · filed 2021-05-07 | |
| 2019-12-31 | $18.30M 10-Q · filed 2021-05-07 | |
| 2019-09-30 | $7.86M 10-Q · filed 2021-05-07 | |
| 2019-06-30 | $36.28M 10-K · filed 2021-08-25 | |
| 2019-03-31 | $7.34M 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $2.41M 10-Q · filed 2020-05-11 | |
| 2018-09-30 | $15.61M 10-Q · filed 2020-05-11 | |
| 2018-06-30 | $17.66M 10-K · filed 2020-08-26 | |
| 2018-03-31 | $6.27M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $2.89M 10-Q · filed 2019-05-07 | |
| 2017-09-30 | $3.05M 10-Q · filed 2019-05-07 | |
| 2017-06-30 | $4.51M 10-K/A · filed 2019-11-06 | |
| 2016-06-30 | $4.80M 10-K · filed 2018-08-27 | |
| 2015-06-30 | $9.76M 10-K · filed 2017-09-07 | |
| 2014-06-30 | $8.38M 10-K · filed 2016-08-29 | |
| 2013-06-30 | $1.10M 10-K · filed 2015-08-31 | |
| 2012-06-30 | $847.00K 10-K · filed 2014-08-29 | |
| 2011-06-30 | $5.35M 10-K · filed 2013-08-29 | |
| 2010-06-30 | $3.26M 10-K · filed 2012-08-29 | |
| 2009-06-30 | $975.00K 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |